Bandingkan Harga & Kinerja Tripar Multivision Plus Tbk. (RAAM) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Tripar Multivision Plus Tbk. dan Organon Pharma Indonesia Tbk.: Tripar Multivision Plus Tbk. diperdagangkan di Rp176 (kapitalisasi pasar 1,23 T, volume 24 jam 1,26 jt), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Tripar Multivision Plus Tbk. jauh lebih besar — sekitar 11,8× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| RAAM | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 1,23 T | 104,4 M |
Volume | 1,26 jt | — |
Lot | 12,56 rb | — |
Perputaran | 222,66 jt | — |
Harga Rata-rata | 177,28 | — |
Nilai Transaksi | 222,66 jt | — |
Harga Ekuilibrium Indikatif | 176 | — |
Volume Ekuilibrium Indikatif | 1,39 rb | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Tripar Multivision Plus Tbk.
PT Tripar Multivision Plus Tbk (“the Company”) was establishedbased on Deed of Establishment of Limited Liability Company No. 17 dated 6 December 1990 drawn up before Adlan Yulizar, S.H., notary in Jakarta.
Selengkapnya di halaman RAAM →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
